Prurigo nodularis (PN) is a persistent and inflammatory dermatological condition characterized by chronic itching and the formation of hardened nodules, significantly impacting the affected individuals' quality of life and psychological well-being. The management of PN poses challenges due to the limited efficacy and undesirable side effects associated with current interventions. This article examines sixteen patients affected by PN treated with dupilumab, a fully human monoclonal antibody targeting interleukin IL-4 and IL-13 signaling. This involves a retrospective descriptive statistical analysis. In all patients, dupilumab proves to be an effective drug in achieving disease clearance, as indicated by all the parameters considered as assessed by both physicians and patients at each evaluation point (Week 6, Week 16, Week 32, Week 52, Week 68, and Week 84), in comparison to the initial baseline.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10856572PMC
http://dx.doi.org/10.3390/jcm13030878DOI Listing

Publication Analysis

Top Keywords

week week
20
prurigo nodularis
8
week
6
dupilumab treatment
4
treatment prurigo
4
nodularis real-life
4
real-life effectiveness
4
effectiveness weeks
4
weeks prurigo
4
nodularis persistent
4

Similar Publications

Background: Advancements in mobile technology have paved the way for innovative interventions aimed at promoting physical activity (PA).

Objective: The main objective of this feasibility study was to assess the feasibility, usability, and acceptability of the More In Action (MIA) app, designed to promote PA among older adults. MIA offers 7 features: personalized tips, PA literacy, guided peer workouts, a community calendar, a personal activity diary, a progression monitor, and a chatbot.

View Article and Find Full Text PDF

Background: Evidence-based digital therapeutics represent a new treatment modality in mental health, potentially providing cost-efficient, accessible means of augmenting existing treatments for chronic mental illnesses. CT-155/BI 3972080 is a prescription digital therapeutic under development as an adjunct to standard of care treatments for patients 18 years of age and older with experiential negative symptoms (ENS) of schizophrenia. Individual components of CT-155/BI 3972080 are designed based on the underlying principles of face-to-face treatment.

View Article and Find Full Text PDF

Percutaneous intra-meniscal platelet-rich plasma (PRP) is a promising tool for managing low-grade meniscal injuries in non-athletic patients. The study evaluates the clinical and radiological outcomes of PRP intra-meniscal injection in meniscal tears. Forty-eight patients were injected with 3 injections of PRP at an interval of one week with a standardised technique under sonographic guidance.

View Article and Find Full Text PDF

Wheelchair part failures and repairs have significantly increased over the last decade, leading to severe consequences for wheelchair users. Servicing these devices by wheelchair repair technicians has reduced part failures. However, no tools or technologies have been developed to support servicing in practice.

View Article and Find Full Text PDF

Objective: Sleep deprivation and reduced sleep quality are common in adolescents and negatively impact their physical and mental wellbeing. This study evaluates the effect of a participatory-developed school-based healthy sleep intervention for adolescents.

Method: A 16-week long intervention, cocreated with adolescents, was conducted with two schools with four schools serving as measurement-only controls.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!